The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

State of the Art

Management of cardiogenic shock

EuroIntervention 2021;17:451-465. DOI: 10.4244/EIJ-D-20-01296

1. Heart Center Leipzig at University of Leipzig, Leipzig, Germany; 2. Leipzig Heart Institute, Leipzig, Germany; 3. University Heart Center Luebeck, Luebeck, Germany; 4. Klinikum Ludwigshafen, Ludwigshafen, Germany

Despite the rapidly evolving evidence base in modern cardiology, progress in the area of cardiogenic shock remains slow, with short-term mortality still reaching 40-50%, relatively unchanged in recent years. Despite advances with an increase in the number of clinical trials taking place in this admittedly difficult-to-study area, the evidence base on which we make day-to-day decisions in clinical practice remains relatively sparse. With only definitive evidence for early revascularisation and the relative ineffectiveness of intra-aortic balloon pumping, most aspects of patient management are based on expert consensus, rather than randomised controlled trials. This updated 2020 review will outline the management of CS mainly after acute myocardial infarction with major focus on state-of-the-art treatment based on randomised clinical trials or matched comparisons if available.

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
A multicentre, prospective, randomised controlled trial to assess the safety and effectiveness of cooling as an adjunctive therapy to percutaneous intervention in patients with acute myocardial infarction: the COOL AMI EU Pivotal Trial